Staphylococcus aureus Infections - Pipeline Review, H2 2015

Staphylococcus aureus Infections - Pipeline Review, H2 2015

Code: GMDHC7301IDB | Published: Dec-2015 | Pages: 538 | Global Markets Direct
Price :

* Required Fields



Staphylococcus aureus Infections - Pipeline Review, H2 2015


Global Markets Directs, Staphylococcus Aureus Infections - Pipeline Review, H2 2015, provides an overview of the Staphylococcus Aureus Infectionss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Absynth Biologics Limited
Actelion Ltd
Adenium Biotech ApS
AIMM Therapeutics B.V.
Alchemia Limited
Allergan Plc
AlphaMab Co., Ltd
Alvogen Korea
AmpliPhi Biosciences Corporation
AnGes MG, Inc.
Aphios Corporation
Arsanis Biosciences GmbH
AstraZeneca Plc
Aureogen Biosciences, Inc.
Aurigene Discovery Technologies Limited
Bharat Biotech International Limited
BioDiem Ltd
Biomar Microbial Technologies
BioSource Pharm, Inc.
C3 Jian, Inc
Cellceutix Corporation
Cempra, Inc.
ContraFect Corporation
CrystalGenomics, Inc.
CSA Biotechnologies LLC
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
DesignMedix, Inc.
Destiny Pharma Limited
Dong-A Socio Group
Ensol Biosciences Inc.
Evaxion Biotech
Excelimmune, Inc.
F. Hoffmann-La Roche Ltd.
Galapagos NV
GangaGen Inc.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Hsiri Therapeutics, LLC
Humabs BioMed SA
Ildong Pharmaceutical Co., Ltd.
Imaxio SA
Immupharma Plc
ImmuVen, Inc.
Integrated BioTherapeutics, Inc.
iNtRON Biotechnology Inc.
ioGenetics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lascco SA
LegoChem Biosciences, Inc
Lytix Biopharma AS
Madam Therapeutics B.V.
MedImmune, LLC
Melinta Therapeutics, Inc
Merck & Co., Inc.
MGB Biopharma Limited
Microbiotix, Inc.
MicuRx Pharmaceuticals, Inc.
MorphoSys AG
Morphotek, Inc.
Motif BioSciences, Inc.
Nabriva Therapeutics AG
NanoBio Corporation
NovaBay Pharmaceuticals, Inc.
Novabiotics Limited
NovaDigm Therapeutics, Inc.
Novan, Inc.
NovoBiotic Pharmaceuticals, LLC
Omnia Molecular Ltd.
Oragenics, Inc.
Pepscan Presto BV
Pfizer Inc.
PharmaIN Corporation
Phico Therapeutics Limited
Phylogica Limited
Pono Pharma
Procarta Biosystems Ltd
QureTech Bio AB
Redx Pharma Plc
Sarepta Therapeutics, Inc.
Savara Inc.
Sentinella Pharmaceuticals, Inc.
Soligenix, Inc.
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syntiron LLC
Taejoon Pharm Co., Ltd.
TAXIS Pharmaceuticals, Inc.
Techulon, Inc.
Telephus Medical LLC
Tetraphase Pharmaceuticals Inc.
Theravance Biopharma, Inc.
United Therapeutics Corporation
Valevia UK Limited
Varinel, Inc.
Wintermute Biomedical LLC
Wockhardt Limited
XBiotech USA, Inc.
Yungjin Pharm. Co., Ltd.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients